SELECT PUBLICATIONS
Cassidy J et al. XELOX compared to FOLFOX4: Survival and response results from XELOX-1/NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC). Proc ASCO 2007;Abstract 4030.
Ellis LM et al. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005;23(22):4853-5. No abstract available
Grothey A et al. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE). Proc ASCO 2007;Abstract 4036.
Gruenberger B et al. Effectiveness of neoadjuvant chemotherapy including bevacizumab in patients with resectable colorectal cancer liver metastases. Proc ASCO 2007;Abstract 4060.
Kabbinavar F et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21(1):60-5. Abstract
Maindrault-Goebel F et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. Proc ASCO 2007;Abstract 4013.
Maindrault-Goebel F et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 2004;15(8):1210-4. Abstract
Michael M et al. Vandetanib with mFOLFOX6 in advanced colorectal adenocarcinoma: An open-label, multicenter phase I study. Proc ASCO 2007;Abstract 4095.
Morabito A et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions. Oncologist 2006;11(7):753-64.Abstract
Nordlinger B et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. Proc ASCO 2007;Abstract LBA5.
Saltz L et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. Proc ASCO 2007a;Abstract 4028.
Saltz LB et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan
compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin Oncol 2007b;25(29):4557-61. Abstract
Saunders M et al. Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: An open-label, multicenter phase I study. Proc ASCO 2007;Abstract 4085.
Tang PA et al. Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007;25(29):4562-8. Abstract
